November 23, 2016 - By Darrin Black · 0 Comments
The stock of Achaogen Incorporated (NASDAQ:AKAO) registered an increase of 1.77% in short interest. AKAO’s total short interest was 569,200 shares in November as published by FINRA. Its up 1.77% from 559,300 shares, reported previously. With 290,600 shares average volume, it will take short sellers 2 days to cover their AKAO’s short positions. The short interest to Achaogen Incorporated’s float is 3.79%. About 244,732 shares traded hands. Achaogen Inc (NASDAQ:AKAO) has risen 29.76% since April 21, 2016 and is uptrending. It has outperformed by 24.43% the S&P500.
Achaogen, Inc. is a clinical-stage biopharmaceutical company. The company has a market cap of $134.37 million. The Firm is engaged in the discovery, development and commercialization of antibacterials to treat multi-drug resistant gram-negative infections. It currently has negative earnings. The Firm is developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections due to MDR Enterobacteriaceae, including carbapenem-resistant enterobacteriaceae (CRE).
Insitutional Activity: The institutional sentiment decreased to 1.07 in 2016 Q2. Its down 0.15, from 1.22 in 2016Q1. The ratio turned negative, as 8 funds sold all Achaogen Inc shares owned while 10 reduced positions. 10 funds bought stakes while 12 increased positions. They now own 13.87 million shares or 102.18% more from 6.86 million shares in 2016Q1.
Goldman Sachs Gp owns 25,731 shares or 0% of their US portfolio. Polar Cap Limited Liability Partnership reported 100,000 shares or 0.01% of all its holdings. The Illinois-based Northern Tru has invested 0% in Achaogen Inc (NASDAQ:AKAO). Axa has invested 0% of its portfolio in Achaogen Inc (NASDAQ:AKAO). Art Advsr Lc last reported 0.01% of its portfolio in the stock. Nomura Holding accumulated 25,100 shares or 0% of the stock. Baker Bros Advsrs L P has 100,000 shares for 0% of their US portfolio. The United Kingdom-based Blackrock Grp Ltd has invested 0% in Achaogen Inc (NASDAQ:AKAO). Morgan Stanley accumulated 48,782 shares or 0% of the stock. Blackrock Institutional Co Na, a California-based fund reported 103,851 shares. Vanguard Gru accumulated 358,478 shares or 0% of the stock. Tfs Ltd Llc accumulated 13,587 shares or 0.01% of the stock. Acadian Asset Mgmt Lc has invested 0% of its portfolio in Achaogen Inc (NASDAQ:AKAO). Cornerstone Mgmt Limited Liability Company holds 2,500 shares or 0% of its portfolio. Sphera Funds Management Ltd holds 1.24% of its portfolio in Achaogen Inc (NASDAQ:AKAO) for 1.26M shares.
Insider Transactions: Since September 27, 2016, the stock had 0 insider buys, and 2 insider sales for $20,217 net activity. Wise Blake sold $15,620 worth of stock. On Tuesday, September 27 Sarpangal Zeryn sold $4,597 worth of the stock or 1,069 shares.
Out of 4 analysts covering Achaogen (NASDAQ:AKAO), 2 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 50% are positive. Achaogen has been the topic of 4 analyst reports since March 16, 2016 according to StockzIntelligence Inc. The rating was downgraded by Needham to “Hold” on Wednesday, March 16. The stock of Achaogen Inc (NASDAQ:AKAO) has “Buy” rating given on Wednesday, November 2 by Aegis Capital. On Tuesday, June 14 the stock rating was upgraded by Wedbush to “Outperform”. The stock of Achaogen Inc (NASDAQ:AKAO) earned “Market Perform” rating by Cowen & Co on Thursday, March 31.
Achaogen, Inc., incorporated on November 26, 2002, is a clinical-stage biopharmaceutical company. The Firm is engaged in the discovery, development and commercialization of antibacterials to treat multi-drug resistant (MDR) gram-negative infections. The Firm is developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections due to MDR Enterobacteriaceae, including carbapenem-resistant enterobacteriaceae (CRE). Plazomicin is an aminoglycoside designed to overcome clinically relevant aminoglycoside resistance mechanisms. In addition, its research and development pipeline includes two programs that specifically target Pseudomonas aeruginosa or Acinetobacter baumannii infections, which include a program to discover and develop small molecule inhibitors of LpxC, which is an enzyme essential for the synthesis of the outer membrane of gram-negative bacteria, and a therapeutic antibody program. The Company’s development plan for plazomicin includes over two Phase III clinical trials.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Darrin Black